Abstract
Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case of sustained virologic suppression 18 months after discontinuation of long-acting cabotegravir/rilpivirine despite inadequate adherence to oral antiretroviral therapy.